INSPIRE Phase 2 SABR Prostate Cancer Trial NCT07552168
Summary
INSPIRE (NCT07552168) is a Phase II, single-arm, multi-centre prospective clinical trial evaluating next-generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. The trial incorporates toxicity reduction strategies and is registered with ClinicalTrials.gov with an indexed date of April 27, 2026. This represents a new clinical trial entry in the prostate cancer radiotherapy research landscape across Irish centres.
“This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
INSPIRE (NCT07552168) is a newly registered Phase II clinical trial on ClinicalTrials.gov, sponsored by Irish institutions, evaluating next-generation Stereotactic Ablative Radiotherapy (SABR) for prostate cancer patients at low, intermediate, and eligible high-risk levels. The trial incorporates toxicity reduction strategies and is designed as a single-arm, multi-centre prospective study.
Healthcare providers, clinical investigators, and patients interested in prostate cancer radiotherapy research should note this trial's registration. The study is now discoverable via ClinicalTrials.gov under NCT07552168, and enrolment information may be available through the linked original document.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INSPIRE: INnovative SABR for Prostate Cancer All IREland
Phase 2 NCT07552168 Kind: PHASE2 Apr 27, 2026
Abstract
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies
Conditions: Prostate Adenocarcinoma
Interventions: Next generation Stereotactic Ablative Radiotherapy (SABR)
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.